COMMUNIQUÉS West-GlobeNewswire

-
Saniona completes treatment in Phase 2a Prader-Willi syndrome trial and initiates open label extension study
07/01/2019 -
Galapagos starts first Phase 1 trial with Toledo compound
07/01/2019 -
Irina Maligina: Changes in the Board of Olmafarm, the main shareholder of Olainfarm, are illegal and will not affect the work of JSC Olainfarm
07/01/2019 -
Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018
07/01/2019 -
Biocartis Group NV: Biocartis Announces Achieving its 2018 Key Business Objectives
07/01/2019 -
VALNEVA Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
07/01/2019 -
VALNEVA annonce des résultats intermédiaires de Phase 1 positifs pour son candidat vaccin contre le Chikungunya
07/01/2019 -
Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus
07/01/2019 -
Biocartis Group NV: Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market
07/01/2019 -
Addex Trading Update: Completes 2018 with Strong Cash Position
07/01/2019 -
Innate Pharma : Upcoming investor conferences
07/01/2019 -
Innate Pharma : Prochains rendez-vous investisseurs
07/01/2019 -
Xenon Pharmaceuticals Outlines 2019 Key Milestones
07/01/2019 -
Adverum Biotechnologies Provides 2019 Outlook
07/01/2019 -
Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018
07/01/2019 -
Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
06/01/2019 -
Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
06/01/2019 -
Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference
06/01/2019 -
Executive Women In Bio Releases First Annual Directory of Boardroom Ready Executive Profiles
05/01/2019
Pages